Multi interventional study exploring HIV-1 residual replication: a step towards HIV-1 eradication and sterilizing cure

• Grant number: 13/11323-5
• Support Opportunities: Regular Research Grants
• Start date: March 01, 2015
• End date: February 28, 2018
• Field of knowledge: Health Sciences - Medicine
• Principal Investigator: Ricardo Sobhie Diaz
• Grantee: Ricardo Sobhie Diaz
• Host Institution: Escola Paulista de Medicina (EPM). Universidade Federal de São Paulo (UNIFESP). Campus São Paulo. São Paulo , SP, Brazil
• Associated researchers: Alberto José da Silva Duarte ; Ermelindo Della Libera Junior ; Luiz Mário Ramos Janini ; Maria Cecilia Araripe Sucupira ; Telma Miyuki Oshiro Sumida

Abstract

This is an interventional proof of concept pilot study to explore the residual HIV replication. Thirty patients under effective HAART for over 2 years will be randomized after recruitment to six different groups and followed by 48 weeks. Group 1. Five patients will receive no further intervention in this group (control group) Group 2. Five patients will receive antiretroviral intensification with maraviroc and dolutegravir for 48 weeks. Group 3. Five patients will receive antiretroviral intensification with maraviroc and dolutegravir and the Sirtuin Histone deacetylase inhibitor nicotinamide for 48 weeks. Group 4. Five patients will receive antiretroviral intensification with maraviroc and dolutegravir for 48 weeks and the gold salt auranofin for 24 weeks. Group 5. Five patients will receive antiretroviral intensification with dolutegravir for 48 weeks, and dendritic cell vaccine.* Group 6. Five patients will receive antiretroviral intensification with dolutegravir for 48 weeks, dendritic cell vaccine, the Sirtuin Histone deacetylase inhibitor nicotinamide for 48 weeks, and gold salt for 24 weeks.* *These groups will not receive maraviroc intensification due to its potential effect in decreasing the chemotactic activity of dendritic cells (AU)

Scientific publications

(7)

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

DIAZ, RICARDO SOBHIE; SHYTAJ, IART LUCA; GIRON, LEILA B.; OBERMAIER, BENEDIKT; LIBERA, JR., ERMELINDO DELLA; GALINSKAS, JULIANA; DIAS, DANILO; HUNTER, JAMES; JANINI, MARIO; GOSUEN, GISELE; et al. Potential impact of the antirheumatic agent auranofin on proviral HIV-1 DNA in individuals under intensified antiretroviral therapy: Results from a randomised clinical trial. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, v. 54, n. 5, p. 592-600, NOV 2019. (13/11323-5)

SADIA SAMER; MUHAMMAD SHOAIB ARIF; LEILA BERTONI GIRON; JEAN PAULO LOPES ZUKUROV; JAMES HUNTER; BRUNA TERESA SANTILLO; GISLENE NAMIYAMA; JULIANA GALINSKAS; SHIRLEY VASCONCELOS KOMNINAKIS; TELMA MIYUKI OSHIRO; et al. Nicotinamide activates latent HIV-1 ex vivo in ART suppressed individuals, revealing higher potency than the association of two methyltransferase inhibitors, chaetocin and BIX01294. Brazilian Journal of Infectious Diseases, v. 24, n. 2, p. 150-159, 2020-06-26. (13/11323-5)

SHYTAJ, IART LUCA; PROCOPIO, FRANCESCO ANDREA; TAREK, MOHAMMAD; CARLON-ANDRES, IRENE; TANG, HSIN-YAO; GOLDMAN, AARON R.; MUNSHI, MOHAMEDHUSEN; PAL, VIRENDER KUMAR; FORCATO, MATTIA; SREERAM, SHEETAL; et al. Glycolysis downregulation is a hallmark of HIV-1 latency and sensitizes infected cells to oxidative stress. EMBO MOLECULAR MEDICINE, v. 13, n. 8, JUL 2021. (13/11323-5, 19/17461-7)

AMINI, RAZIEH; KARAMPOOR, SAJAD; ZAHEDNASAB, HAMID; KEYUANI, HOSSEIN; GHEIASIAN, MASOUD; JALILIAN, FARID AZIZI. Serum levels of matrix metalloproteinase-2,-9, and vitamin D in patients with multiple sclerosis with or without herpesvirus-6 seropositivity. Brazilian Journal of Infectious Diseases, v. 24, n. 2, p. 144-159, MAR-APR 2020. (13/11323-5)

DE ALMEIDA BAPTISTA, MARCELLA VASSAO; DA SILVA, LAIS TEODORO; SAMER, SADIA; OSHIRO, TELMA MIYUKI; SHYTAJ, IART LUCA; GIRON, LEILA B.; PENA, NATHALIA MANTOVANI; CRUZ, NICOLLY; GOSUEN, GISELE CRISTINA; ABRAO FERREIRA, PAULO ROBERTO; et al. mmunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical tria. AIDS RESEARCH AND THERAPY, v. 19, n. 1, JAN 12 2022. (19/17461-7, 13/11323-5)

SADRAEIAN, MOHAMMAD; DA CRUZ, EDGAR FERREIRA; BOYLE, ROSS W.; BAHOU, CALISE; CHUDASAMA, VIJAY; RAMOS JANINI, LUIZ MARIO; DIAZ, RICARDO SOBHIE; GUIMARAES, FRANCISCO E. G.. Photoinduced Photosensitizer-Antibody Conjugates Kill HIV Env-Expressing Cells, Also Inactivating HIV. ACS OMEGA, v. 6, n. 25, p. 16524-16534, JUN 29 2021. (13/11323-5, 13/07276-1)

SAMER, SADIA; NAMIYAMA, GISLENE; OSHIRO, TELMA; ARIF, MUHAMMAD SHOAIB; DA SILVA, WANESSA CARDOSO; ARARIPE SUCUPIRA, MARIA CECILIA; JANINI, LUIZ MARIO; DIAZ, RICARDO SOBHIE. Evidence of Noncompetent HIV after Ex Vivo Purging Among ART-Suppressed Individuals. AIDS Research and Human Retroviruses, v. 33, n. 10, p. 993-994, OCT 2017. (13/11323-5)